Prevents postmenopausal osteoporosis. ANDA 90877, held by Apotex. Risedronate Sodium.
As of Nov 16, 2026, ANDA 90877 (Risedronate Sodium), held by Apotex, was first approved by FDA on Nov 30, 2015, with 2 approved supplements and 0 published complete response letters.
Risedronate sodium tablets, USP are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis Treatment to increase bone mass in men with osteoporosis
| Nov 30, 2015 | Original application | Approved | None posted |
| Jun 10, 2014 | Original application | Approved | None posted |
| Risedronate Sodium35MG · tablet;oral | Risedronate Sodium | Rx |
| Risedronate Sodium75MG · tablet;oral | Risedronate Sodium | Rx |
| Risedronate Sodium150MG · tablet;oral | Risedronate Sodium | Rx |
| May 12, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 15, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 30, 2015 | Original application | Approved | None posted |
| Jun 10, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters